Edwards Lifesciences Corporation (EW) Upgraded to Buy at Truist Securities

Market Context

Edwards Lifesciences Corporation operates in the Healthcare sector. The stock currently trades at $97.20 with a market capitalization of $49.5B. The stock has gained 12.2% over the past 52 weeks.

Analyst upgrades often act as catalysts for near-term price movement, particularly when they come from major firms with significant institutional following. Truist Securities's upgrade suggests their analysts see improving fundamentals, a more favorable risk-reward profile, or upcoming catalysts that could drive the stock higher.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Edwards Lifesciences Corporation

Among the 10 most recent ratings: 9 Buy, 1 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Nov 04, 2026	Truist Securities	Buy	N/A
Oct 07, 2026	Barclays	Overweight	N/A
Sep 11, 2026	BTIG	Buy	N/A
Jul 24, 2026	Leerink Partners	Outperform	N/A
Jul 24, 2026	Piper Sandler	Overweight	N/A

Related Tools: Analyst Ratings Dashboard | View EW Stock Page